Key Takeaways Novartis' core EPS rose to $2.25 from$2.06, as sales increased 8% to $13.9 billion.Kisqali, Kesimpta, Pluvicto and Scemblix drove growth, offsetting generic hits to Entresto and Tasigna.Novartis agreed to buy Avidity for$12B to strengthen its neuroscience pipeline.Swiss pharma giant Novartis AG (NVS) reported core earnings per share (excluding one-time charges) of $2.25 in the third quarter, which missed the Zacks Consensus Estimate by a penny. Nonetheless, the figure was up from$2.06 repor ...